Trial Profile
A Single-patient Study of Repeat-dose Administration of ProMetic Plasminogen (Human) Intravenous Infusion in an Adult With Hypoplasminogenemia
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Plasminogen (Primary)
- Indications Type I plasminogen deficiency
- Focus Expanded access; Therapeutic Use
- Sponsors ProMetic BioTherapeutics
- 22 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 01 Sep 2017 New trial record